Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis Cavazzini F, Hernandez JA, Gozzetti A, Russo Rossi A, De Angeli C, Tiseo R, Bardi A, Tammiso E, Crupi R, Lenoci MP, Forconi F, Lauria F, Marasca R, Maffei R, Torelli G, González M, Martin-Jimenez P, Maria Hernandez J, Rigolin GM, Cuneo A. British Journal of Haematology 142:529-37. FI: 4.597 (Q1) Prognostic value of Immunophenotyping Multiple Myeloma: a study by the GEM and the Pethema cooperative study groups on Patients Uniformly treated with high dose therapy Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, Rosiñol L, Montejano L, Bladé J, Martínez R, de la Rubia J, Diaz-Mediavilla J, Sureda A, Ribera JM, Ojanguren JM, de Arriba F, Palomera L, Terol, MJ, Orfao A, San Miguel JF. PETHEMA Study Group. GEM Study Group. Journal of Clinical Oncology 26: 2737-44. FI: 17.793 (Q1) Molecular and Epidemiological findings of childhood acute leukemia in Costa Rica Santamaría-Quesada C, Vargas M, Venegas P, Calvo M, Obando C, Valverde B, Cartín W, Carrillo JM, Jimenez R, González M. Journal of Pediatric Hematology Oncology 31(2):131-5. FI: 1.022 (Q3) Primary cutaneous T-cell lymphoproliferative disorder of donor origin after allogeneic haematopoietic stem-cell transplantation Santos-Briz A, Romo A, Antúnez P, Román C, Alcoceba M, Garcia JL, Vazquez L, González M, Unamuno P. Clinical and Experimental Dermatology 34(8):e778-81. FI: 1.550 (Q3) Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-transretinoic acid and anthracycline chemotherapy: characteristics, outcome and prognostic factors Montesinos P, Bergua JM, Vellenga E, Rayón C, Parody R, de la Serna J, León A, Esteve J, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA. Blood 113(4):775-83. FI: 10.555 (Q1) - Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González M, Abella E, Delgado J, Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM) a New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leucemia Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E. Journal of Clinical Oncology 27(27):4578-84. FI: 17.793 (Q1) Bone marrow mesenchymal stem cells from infants with MLL-AF4, acute leukemia harbor and express the MLL-AF4 fusion gene Menendez P, Catalina P, Rodríguez R, Melen GJ, Bueno C, Arriero M, García-Sánchez F, Lassaletta A, García-Sanz R, García-Castro J. Journal of Experimental Medicine 206(13):3131-41. FI: 14.505 (Q1) A randomized phase 3 study of tipifarnib compared to best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 70 years or older Harousseau JL, Martinelli G, Jedrzejczak WW, Brandwein JM, Bordessoule D, Masszi , Ossenkoppele GJ, Alexeeva JA, Beutel G, Maertens J, Vidriales MB, Dombret H, Thomas X, Burnett AK, Robak T, Khuageva NK, Golenkov AK, Tothova E, Mollgard L, Park YC, Bessems A, De Porre P, Howes AJ. Blood 114(6):1166-73. FI: 10.555 (Q1) Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia Dimopoulos MA, Gertz MA, Kastritis E, García-Sanz R, Kimby EK, Leblond V, Fermand JP, Merlini G, Morel P, Morra E, Ocio EM, Owen R, Ghobrial IM, Seymour J, Kyle RA, Treon SP. Journal of Clinical Oncology 27(1):120-6. FI: 17.793 (Q1) International prognostic scoring system for Waldenstrom's macroglobulinemia Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, Crowley J, Ocio EM, García-Sanz R, Treon SP, Leblond V, Kyle RA, Barlogie B, Merlini G. Blood 113:4163-4170. FI: 10.555 (Q1)
|
